|Bid||103.00 x 0|
|Ask||105.00 x 0|
|Day's Range||101.00 - 105.75|
|52 Week Range||1.17 - 181.90|
|Beta (5Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep 28, 2022 - Oct 03, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||155.00|
Subscribe to Yahoo Finance Plus to view Fair Value for AVCT.L
LONDON & WETHERBY, England, June 30, 2022--Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, has exercised its renewal option as part of the ongoing collaboration with Avacta, triggering a license renewal fee payment to Avacta of $2 m
The Avacta Group Plc ( LON:AVCT ) share price has had a bad week, falling 12%. But over three years the performance has...
CAMBRIDGE & WETHERBY, England, April 13, 2022--Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics ("AffyXell"), a joint venture between Avacta and Daewoong Pharmaceutical ("Daewoong") in South Korea.